Global FKRP Registry: observations in more than 300 patients with Limb Girdle Muscular Dystrophy R9

Lindsay B Murphy, Olivia Schreiber-Katz, Karen Rafferty, Agata Robertson, Ana Topf, Tracey A Willis, Marcel Heidemann, Simone Thiele, Laurence Bindoff, Jean-Pierre Laurent, Hanns Lochmüller, Katherine Mathews, Claudia Mitchell, John Herbert Stevenson, John Vissing, Lacey Woods, Maggie C Walter, Volker Straub, Lindsay B Murphy, Olivia Schreiber-Katz, Karen Rafferty, Agata Robertson, Ana Topf, Tracey A Willis, Marcel Heidemann, Simone Thiele, Laurence Bindoff, Jean-Pierre Laurent, Hanns Lochmüller, Katherine Mathews, Claudia Mitchell, John Herbert Stevenson, John Vissing, Lacey Woods, Maggie C Walter, Volker Straub

Abstract

Objective: The Global FKRP Registry is a database for individuals with conditions caused by mutations in the Fukutin-Related Protein (FKRP) gene: limb girdle muscular dystrophy R9 (LGMDR9, formerly LGMD2I) and congenital muscular dystrophies MDC1C, Muscle-Eye-Brain Disease and Walker-Warburg Syndrome. The registry seeks to further understand the natural history and prevalence of FKRP-related conditions; aid the rapid identification of eligible patients for clinical studies; and provide a source of information to clinical and academic communities.

Methods: Registration is patient-initiated through a secure online portal. Data, reported by both patients and their clinicians, include: age of onset, presenting symptoms, family history, motor function and muscle strength, respiratory and cardiac function, medication, quality of life and pain.

Results: Of 663 registered participants, 305 were genetically confirmed LGMDR9 patients from 23 countries. A majority of LGMDR9 patients carried the common mutation c.826C > A on one or both alleles; 67.9% were homozygous and 28.5% were compound heterozygous for this mutation. The mean ages of symptom onset and disease diagnosis were higher in individuals homozygous for c.826C > A compared with individuals heterozygous for c.826C > A. This divergence was replicated in ages of loss of running ability, wheelchair-dependence and ventilation assistance; consistent with the milder phenotype associated with individuals homozygous for c.826C > A. In LGMDR9 patients, 75.1% were currently ambulant and 24.6%, nonambulant (unreported in 0.3%). Cardiac impairment was reported in 23.2% (30/129).

Interpretation: The Global FKRP Registry enables the collection of patient natural history data, which informs academics, healthcare professionals and industry. It represents a trial-ready cohort of individuals and is centrally placed to facilitate recruitment to clinical studies.

Conflict of interest statement

The authors report no conflicts of interest relating to this work.

© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Figures

Figure 1
Figure 1
Registration process and data flow in the Global FKRP Registry.
Figure 2
Figure 2
The current age of all genetically confirmed Global FKRP Registry participants (n = 320). The number of male and female patients within each 10‐year age range, from 1 to 9 through to 70–79 years, is presented. Male (black); female (gray).
Figure 3
Figure 3
The current age of LGMDR9 patients with the common FKRP gene mutation (c.826C > A, n = 294). Patient number within each 10‐year age range is further stratified by zygosity of the common FKRP gene mutation and by sex. The difference between homozygous c.826C > A and heterozygous c.826C > A mean ages is significant (P < 0.0001). Homozygous c.826C > A, male (black); Homozygous c.826C > A, female (gray); Heterozygous c.826C > A, male (white); Heterozygous c.826C > A, female (dots).
Figure 4
Figure 4
The age of LGMDR9 patients with the common FKRP gene mutation associated with specific motor functions: (A) the age of LGMDR9 patients at which running ability was lost (n = 171). The difference between homozygous c.826C > A and heterozygous c.826C > A mean ages is significant (P < 0.0001); (B) the current age of ambulant LGMDR9 patients (n = 222); and (C) the current age of LGMDR9 patients who use a wheelchair, either part‐time or full‐time (n = 148). For each graph, patient number within each 10‐year age range is further stratified by zygosity of the common FKRP gene mutation and by sex. Homozygous c.826C > A, male (black); Homozygous c.826C > A, female (gray); Heterozygous c.826C > A, male (white); Heterozygous c.826C > A, female (dots).

References

    1. Beltran‐Valero de Bernabé D, Voit T, Longman C, et al.Mutations in the FKRP gene can cause muscle‐eye‐brain disease and Walker‐Warburg syndrome. J Med Genet 2004;41:e61.
    1. Mercuri E, Brockington M, Straub V, et al. Phenotypic spectrum associated with mutations in the fukutin‐related protein gene. Ann Neurol 2003;53:537–542.
    1. Stensland E, Lindal S, Jonsrud C, et al. Prevalence, mutation spectrum and phenotypic variability in Norwegian patients with Limb Girdle Muscular Dystrophy 2I. Neuromuscul Disord 2011;21:41–46.
    1. Darin N, Kroksmark AK, Ahlander AC, et al. Inflammation and response to steroid treatment in limb‐girdle muscular dystrophy 2I. Eur J Paediatr Neurol 2007;11:353–357.
    1. Godfrey C, Escolar D, Brockington M, et al. Fukutin gene mutations in steroid‐responsive limb girdle muscular dystrophy. Ann Neurol 2006;60:603–610.
    1. Lin YC, Murakami T, Hayashi YK, et al. A novel FKRP gene mutation in a Taiwanese patient with limb‐girdle muscular dystrophy 2I. Brain Dev 2007;29:234–238.
    1. Xu L, Lu PJ, Wang CH, et al. Adeno‐associated virus 9 mediated FKRP gene therapy restores functional glycosylation of alpha‐dystroglycan and improves muscle functions. Mol Ther 2013;21:1832–1840.
    1. Qiao C, Wang CH, Zhao C, et al. Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery. Mol Ther 2014;22:1890–1899.
    1. Gicquel E, Maizonnier N, Foltz SJ, et al. AAV‐mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression. Hum Mol Genet 2017;15:1952–1965.
    1. Vannoy CH, Leroy V, Broniowska K, et al. Metabolomics analysis of skeletal muscles from FKRP‐deficient mice indicates improvement after gene replacement therapy. Sci Rep 2019;11:10070.
    1. Kim J, Oliveira VKP, Yamamoto A, et al. Generation of skeletal myogenic progenitors from human pluripotent stem cells using non‐viral delivery of minicircle DNA. Stem Cell Res 2017;23:87–94.
    1. Bushby K, Lynn S, Straub T, Network T‐N. Collaborating to bring new therapies to the patient–the TREAT‐NMD model. Acta Myol 2009;28:12–15.
    1. Sarkozy A, Bushby K, Beroud C, et al. 157th ENMC International Workshop: patient registries for rare, inherited muscular disorders 25–27 January 2008 Naarden, The Netherlands.Neuromuscul Disord 2008;18:997–1001.
    1. Bladen CL, Salgado D, Monges S, et al. The Treat‐NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 2015;36:395–402.
    1. Bladen CL, Rafferty K, Straub V, et al. The TREAT‐NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum Mutat 2013;34:1449–1457.
    1. Bladen CL, Thompson R, Jackson JM, et al. Mapping the differences in care for 5,000 Spinal Muscular Atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. J Neurol 2014;261:152–163.
    1. Rodger S, Lochmuller H, Tassoni A, et al. The TREAT‐NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases. Orphanet J Rare Dis 2013;8:171.
    1. Vincent KA, Carr AJ, Walburn J, et al. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology 2007;68:1051–1057.
    1. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1:277–299.
    1. Willis TA, Hollingsworth KG, Coombs A, et al. Quantitative magnetic resonance imaging in limb‐girdle muscular dystrophy 2I: a multinational cross‐sectional study. PLoS ONE 2014;28:e90377.
    1. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77–93.
    1. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177–189.
    1. Wang CH, Bonnemann CG, Rutkowski A, et al. Consensus statement on standard of care for congenital muscular dystrophies. J Child Neurol 2010;25:1559–1581.
    1. Hollingsworth KG, Willis TA, Bates MG, et al. Subepicardial dysfunction leads to global left ventricular systolic impairment in patients with limb girdle muscular dystrophy 2I. Eur J Heart Fail 2013;15:986–994.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться